Northwest & Ethical Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Northwest & Ethical Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-800	Closed	-$77.6K	–	372
2018 Q3	$77.6K	Sell	800 -400	-33%	-$39.9K	﹤0.01%	340
2018 Q2	$113K	Hold	1,200	–	–	0.01%	347
2018 Q1	$97.3K	Buy	1,200 +400	+50%	+$34.3K	0.01%	343
2017 Q4	$71.3K	Sell	800 -200	-20%	-$17.4K	﹤0.01%	344
2017 Q3	$93.1K	Buy	1,000 +400	+67%	+$35.3K	0.01%	345
2017 Q2	$72.7K	Buy	+600	New	+$54.6K	﹤0.01%	357

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northwest & Ethical Investments's BMRN Position: Q4 2018 in Review

Northwest & Ethical Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2018, closing a stake of 800 shares — an estimated $77.6K sold.

Northwest & Ethical Investments first reported a position in BMRN in Q2 2017 and held it in 6 quarters. The position peaked at $113K in Q2 2018. 472 funds tracked by Wall St. Rank hold BMRN as of Q4 2018.

Northwest & Ethical Investments reported no remaining BioMarin Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Northwest & Ethical Investments sold 800 BioMarin Pharmaceuticals shares in Q4 2018, an estimated $77.6K.
Northwest & Ethical Investments first reported a position in BioMarin Pharmaceuticals in Q2 2017 and held it in 6 quarters.
Northwest & Ethical Investments's BioMarin Pharmaceuticals position peaked at $113K in Q2 2018.
472 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2018.

Based on Northwest & Ethical Investments's 13F filing for Q4 2018, filed 8 Jul 2025.